Heat shock protein 90 (Hsp90) is an emerging target for cancer therapy due to its important role in maintaining the activity and stability of key oncogenic signaling proteins. We show here that the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion protein, presumed to be the oncogenic driver in about 5% of patients with non-small cell lung cancer (NSCLC), is associated with Hsp90 in cells and is rapidly degraded upon exposure of cells to IPI-504. We find EML4-ALK to be more sensitive to Hsp90 inhibition than either HER2 or mutant epidermal growth factor receptor (EGFR) with an inhibitory concentration (IC) 50 for protein degradation in the low nanomolar range. This degradation leads to a potent inhibition of downstream signaling pathways and to the induction of growth arrest and apoptosis in cells carrying the EML4-ALK fusion. To generate a causative link between the expression of EML4-ALK and sensitivity to IPI-504, we introduced an EML4-ALK cDNA into HEK293 cells and show that the expression of the fusion protein sensitizes cells to IPI-504 both in vitro and in vivo. In a xenograft model of a human NSCLC cell line containing the ALK rearrangement, we observe tumor regression at clinically relevant doses of IPI-504. Finally, cells that have been selected for resistance to ALK kinase inhibitors retain their sensitivity to IPI-504. We have recently observed partial responses to administration of IPI-504 as a single agent in a phase 2 clinical trial in patients with NSCLC, specifically in patients that carry an ALK rearrangement. This study provides a molecular explanation for these clinical observations.
Introduction
Heat shock protein 90 (Hsp90) is an abundant cellular chaperone protein that maintains the stability, activity and sorting of its protein substrates, which are also called client proteins (Young et al., 2001; Pearl and Prodromou, 2006) . Upon inhibition of the Hsp90 chaperone, client proteins are rapidly degraded through the proteasome (Connell et al., 2001 ). Hsp90 has recently become an emerging target for cancer therapeutics (Neckers, 2007) as many of its client proteins are oncoproteins such as HER2 (Munster et al., 2001) , mutant cKIT (Fumo et al., 2004; Dewaele et al., 2008) , mutant epidermal growth factor receptor (EGFR) (Shimamura et al., 2005; Shimamura and Shapiro, 2008) or BCR-ABL (An et al., 2000; Peng et al., 2007) . Consistent with this supportive role in malignant transformation and maintenance of oncogene addiction in some cancers, Hsp90 is overexpressed in cancer cells and overexpression is correlated with disease progression in melanoma (McCarthy et al., 2008) and associated with decreased survival in breast (Pick et al., 2007) , lung (Gallegos Ruiz et al., 2008) and gastrointestinal stromal tumors .
Oncogenic activation of the anaplastic lymphoma kinase (ALK) occurs in various cancer types. In nonsmall cell lung cancer (NSCLC), an intra-chromosomal rearrangement results in the fusion of the N-terminus of the echinoderm microtubule-associated protein-like 4 (EML4) with the C-terminal tyrosine kinase domain of ALK (Soda et al., 2007) . To date, multiple EML4-ALK variants have been identified (Choi et al., 2008; Takeuchi et al., 2009) . All fusion oncoproteins comprise the entire tyrosine kinase domain of ALK and variable portions of the EML4 protein. Dimerization of the fusion protein through the EML4 domain leads to constitutive activation of the ALK kinase and to cellular transformation (Choi et al., 2008; Koivunen et al., 2008) .
IPI-504 (retaspimycin hydrochloride), a water-soluble derivative of 17-AAG, is potent inhibitor of Hsp90 Sydor et al., 2006) . The biological and anti-neoplastic effects of IPI-504 have been demonstrated in multiple in vitro and in vivo models of cancer (Bauer et al., 2006; Peng et al., 2007; Dewaele et al., 2008; Song et al., 2008; Leow et al., 2009) leading to its clinical development in various phase 2 studies (clinicaltrials.gov).
While there is good preclinical rationale for the use of Hsp90 inhibitors in cancer and multiple inhibitors are in clinical development, only few have led to clinical benefit (Modi et al., 2007; Sequist et al., 2010a, b) . This might be due, in part, to the difficulty of finding the right clinical indication for these inhibitors. It is not clear whether Hsp90 inhibitors in the clinic ultimately act through a sensitive client protein that is also an oncoprotein or whether cell killing is mediated through the simultaneous degradation of multiple clients and a more general effect on protein homeostasis.
In a phase 2 trial of IPI-504 in NSCLC, we have recently observed partial responses in patients whose tumor cells contain rearrangements of the ALK locus (Sequist et al., 2010a, b) . Here, we investigate the sensitivity of EML4-ALK as an Hsp90 client protein, whether EML4-ALK is causatively involved in the sensitivity of cancer cells to Hsp90 inhibition and the activity of IPI-504 in xenograft models that express the EML4-ALK fusion protein.
Results and discussion
Observation of clinical benefit in NSCLC patients positive for ALK gene rearrangements following administration of IPI-504 In a recent phase 2 study of IPI-504 in NSCLC, we observed an overall response rate of 7%. Upon molecular characterization of patient tumors, we determined that the response rate was 4% in patients with mutant EGFR and 10% in patients with wild-type EGFR (Sequist et al., 2010a, b) . This was surprising, because we and others had speculated that mutant EGFR would be the sensitive Hsp90 client protein mediating clinical responses to Hsp90 inhibition in this population. When patient tumors were further analyzed for genetic abnormalities, three samples (of 15 available for testing) scored positive for rearrangements involving the ALK locus. Interestingly, all three of these patients showed some degree of tumor shrinkage. Two patients reached 430% tumor shrinkage (PR) and one patient had a 24% tumor shrinkage and stable disease for 47 months (Sequist et al., 2010a, b) .
EML4-ALK is a sensitive client protein of Hsp90
Rearrangements at the ALK locus have been reported in about 5% of NSCLC patients, forming an oncogenic fusion of the N-terminus of EML4 with the C-terminal kinase domain of ALK (Soda et al., 2007) . To determine whether the EML4-ALK fusion protein is a client protein of Hsp90, we incubated the EML4-ALKexpressing NSCLC cell line H3122 with increasing concentrations of IPI-504 and measured the abundance of total and phosphorylated ALK protein by enzymelinked immunosorbent assay ( Figure 1a (Tillotson et al., 2010) that time to degradation is the most sensitive measure of client protein dependency on Hsp90. In this analysis, EML4-ALK is completely degraded by 3 h, whereas it takes about 24 h for most of the HER2 and mutEGFR to be degraded (Figure 1b) . To further confirm that EML4-ALK is indeed a client of Hsp90, we performed immunoprecipitations with an antibody directed against Hsp90a, and detected a protein band at the predicted molecular weight of the fusion protein (90 kDa) with an ALK antibody in Hsp90 immunoprecipitates from H3122 cells but not control cells ( Figure 1c , lanes 1 and 3). We show that both in terms of dose-response and time to degradation, EML4-ALK is a more sensitive client than either mutant EGFR or HER2, proteins previously believed to be some of the most sensitive Hsp90 clients in the cell.
IPI-504 treatment induces EML4-ALK degradation, inhibition of downstream pathways and inhibits cell growth
To investigate the cellular consequences of degrading EML4-ALK, we probed lysates from H3122 cells that had been incubated with IPI-504 for different times with antibodies against ALK and different downstream signaling proteins (Figure 1d ). Upon IPI-504 treatment and EML4-ALK degradation, the active (phosphorylated) forms of ERK and STAT3 are rapidly depleted, whereas AKT and phospho-AKT are depleted on a different timescale. To obtain a mechanistic connection between the expression of EML4-ALK and sensitivity to Hsp90 inhibition, we asked whether transfection of an EML4-ALK cDNA could sensitize a cell to Hsp90 inhibition. Two cDNAs were constructed, one encoding the EML4-ALK fusion protein and the other encoding a mutant version of the fusion where the kinase domain of ALK is inactivated by a point mutation (ALK-KD). cDNAs were transfected into HEK293FT cells and the expression (Figure 2a, lanes 1-3) and activity ( Figure 2a , lanes 4-6) of the fusion proteins monitored by western blot. Large amounts of EML4-ALK fusion proteins are expressed from both constructs, and as expected, the kinase dead mutant (ALK-KD) while expressed, has no enzymatic activity. We then asked how the expression of the active or inactive fusion protein modulates sensitivity to IPI-504. While treatment with either 100 or 1000 nM IPI-504 has very little effect on the growth of HEK293FT cells expressing the kinase dead mutant 
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This sensitizing effect could also be observed in vivo. When tumors formed from EML4-ALK-expressing HEK293FT cells or control HEK293FT tumors in nude mice were treated with 100 mg/kg IPI-504 twice weekly for 2 weeks, significant growth inhibition was seen in the EML4-ALKcontaining tumors, but not the control tumors (Figure 2c) . As it has been estimated that there are 4200 Hsp90 client proteins in the cell, it has been hard to narrow down the exact mechanism of cancer cell growth inhibition after Hsp90 inhibitor treatment. It is not clear whether the cellular effects of Hsp90 inhibition are brought about by general effects on protein homeostasis through the simultaneous inhibition of multiple client proteins or whether they can be traced back to the degradation of a single oncogenic driver protein. We show here through the use of isogenic cell lines that at least in the case of EML4-ALK the latter seems to be the case. This has implications for the future clinical development of Hsp90 inhibitors as our results suggest that patients with cancer subtypes driven by oncoproteins that are very sensitive Hsp90 client proteins might benefit the most from Hsp90 inhibitor treatment.
IPI-504 treatment causes regression in a xenograft model of EML4-ALK-containing NSCLC cells
In most xenograft models, Hsp90 inhibitors cause tumor growth inhibition, but no tumor regression. Consistent with this, the responses to Hsp90 inhibitors in the clinic have so far mostly consisted of induction of stable disease. We asked whether the extreme sensitivity of the EML4-ALK fusion protein to Hsp90 inhibition would translate into tumor regression of the ALK-dependent H3122 cell line in vivo. H3122 cells were injected into the flanks of nude mice and animals were treated with 75 mg/kg of IPI-504 twice weekly. This treatment led to tumor regression, comparable to treatment with the ALK kinase inhibitor PF-1066 (crizotinib) at 50 mg/kg every day (Figure 3a) . We also tested a combination of IPI-504 and PF-1066 and this treatment led to even more profound tumor regression (Figure 3b) . Interestingly, once treatment was stopped, tumors from the PF-1066 arm re-grew more rapidly than tumors in the IPI-504 arm; additionally, an even longer tumor growth delay was observed with the combination of IPI-504 and PF-1066. To confirm degradation of EML4-ALK within these tumors, a separate arm was included in the study where tumors were harvested at different time points after a single injection of IPI-504 and the abundance of the fusion protein over time was monitored using an ALK-specific enzyme-linked immunosorbent assay (Figure 3c ). The result shows that the ALK fusion protein is depleted for 448 h after a single injection of IPI-504. The depletion of EML4-ALK coincides with the appearance of poly (ADPribose) polymerase (PARP) cleavage, an indication of caspase 3 activation and the induction of apoptosis (Figure 3d) . Thus, the exquisite sensitivity of Activity of IPI-504 in EML4-ALK-driven tumor E Normant et al EML4-ALK as a client protein also translates to the in vivo setting and we observe tumor regression in an EML4-ALK-positive NSCLC xenograft model with IPI-504 dosed twice weekly. The observed regressions might be due to the fact that, after a single injection of IPI-504, the fusion protein is depleted for 448 h, leading to the induction of apoptosis (Figures 3c and d) .
Cells selected for resistance to PF-1066 remain sensitive to IPI-504 While tyrosine kinase inhibitors have shown impressive response rates in selected patient populations in NSCLC, clinical resistance to these inhibitors often emerges. Often, the underlying resistance mechanisms are driven by Hsp90 client proteins (for example, EGFR T790M and c-Met), and TKI-resistant NSCLC cell lines are sensitive to Hsp90 inhibitors (Park et al., 2008; . To ask whether cells resistant to PF-1066 would remain sensitive to IPI-504, we conducted an in vitro experiment to select H3122 cells resistant to PF-1066 by incubating cells with the inhibitor. This treatment resulted in a pool of cells (H3122R) that were 12 times less sensitive to PF-1066 than the parental cells. These H3122R cells were also resistant to a structurally different ALK inhibitor (TAE-684) but remained sensitive to IPI-504 (Table 1) . Sequencing of the EML4-ALK gene in the H3122R cells did not reveal any secondary mutations (data not shown), indicating that the resistance might be caused by the activation of alternative signaling pathways that remain sensitive to Hsp90 inhibition. Personalized cancer medicine relies on the ability to match the right drug with the right patient.
To that end, linking somatic genetic alterations in the tumor and response to targeted therapies has become a critical and integral step in cancer drug development. The advent of novel genetic technologies, including high-throughput cancer gene genotyping (Oncomap (Thomas et al., 2007) and Snapshot) as well as fluorescence in situ hybridization, have enabled the identification of these alterations and hence patient subpopulations most likely to benefit from novel therapies. Using these strategies in a retrospective analysis of tumor specimens from our study of IPI-504 in NSCLC, we have discovered an association between ALK rearrangements and response to IPI-504 (Sequist et al., 2010a, b) . Here, we present evidence that this clinical correlation is most likely due to the exquisitely sensitive, rapid and sustained degradation of oncogenic ALK fusions upon treatment with IPI-504. Activity of IPI-504 in EML4-ALK-driven tumor E Normant et al
